Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.54 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.54 |
| ▸ | GCLC | P48506 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26602760 | 0.93 | GRM3 (0.51) | FOLH1GRM3 | |
| SCHEMBL25362802 | 0.91 | FOLH1 (0.46) | FOLH1GRM3 | |
| SCHEMBL2369323 | 0.86 | FOLH1 (0.48) | FOLH1GRM3 | |
| SCHEMBL2369322 | 0.84 | FOLH1 (0.46) | FOLH1GRM3 | |
| SCHEMBL28021364 | 0.81 | GABBR2 (0.42) | GCLC | |
| SCHEMBL1373545 | 0.80 | GRM3 (0.54) | FOLH1GRM3 | |
| SCHEMBL26602758 | 0.80 | FOLH1 (0.52) | FOLH1GRM3 | |
| SCHEMBL25362800 | 0.79 | FOLH1 (0.36) | FOLH1GRM3GCLC | |
| SCHEMBL5053055 | 0.78 | FOLH1 (0.55) | FOLH1GRM3 | |
| SCHEMBL2369327 | 0.78 | FOLH1 (0.45) | FOLH1GRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250064948-A1 | GCPII INHIBITION FOR THE TREATMENT OF SARCOPENIA AND AGING | THE JOHNS HOPKINS UNIVERSITY | 2025-02-27 | — | — | US | claimed |
| WO-2023154939-A2 | GCPII INHIBITION FOR THE TREATMENT OF SARCOPENIA AND AGING | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-08-17 | — | — | WO | claimed |
| US-11167049-B2 | Organ protection in PSMA-targeted radionuclide therapy of prostate cancer | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2021-11-09 | — | — | US | claimed |
| EP-3193914-B1 | ORGAN PROTECTION IN PSMA-TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER | MOLECULAR INSIGHT PHARM INC (US) | 2021-01-20 | — | — | EP | claimed |
| US-20200254120-A1 | ORGAN PROTECTION IN PSMA-TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2020-08-13 | — | — | US | claimed |
| US-10668174-B2 | Organ protection in PSMA-targeted radionuclide therapy of prostate cancer | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2020-06-02 | — | — | US | claimed |
| US-20180207299-A1 | ORGAN PROTECTION IN PSMA-TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2018-07-26 | — | — | US | claimed |
| US-9956305-B2 | Organ protection in PSMA-targeted radionuclide therapy of prostate cancer | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | claimed |
| EP-3193914-A1 | ORGAN PROTECTION IN PSMA-TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER | Molecular Insight Pharmaceuticals, Inc. (US) | 2017-07-26 | — | — | EP | claimed |
| WO-2016040179-A1 | ORGAN PROTECTION IN PSMA-TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-03-17 | — | — | WO | claimed |
| US-20160067361-A1 | ORGAN PROTECTION IN PSMA-TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-03-10 | — | — | US | claimed |
| US-5880112-A | PHOSPHINIC ACID DERIVATIVES; PROSTATE CANCER TREATMENT | GUILFORD PHARMACEUTICALS INC. (US) | 1999-03-09 | — | — | US | claimed |
| US-20260007756-A1 | COMPOUND AND USE THEREOF | COHERENT BIOPHARMA SUZHOU LTD (CN) | 2026-01-08 | — | — | US | disclosed |
| US-12496292-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250127939-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | PURDUE RESEARCH FOUNDATION | 2025-04-24 | — | — | US | disclosed |
| EP-4541378-A2 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | Endocyte, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-5968915-A | INHIBIT GROWTH OF PROSTATE CANCER CELLS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-10-19 | — | — | US | disclosed |
| US-5880112-A | PHOSPHINIC ACID DERIVATIVES; PROSTATE CANCER TREATMENT | GUILFORD PHARMACEUTICALS INC. (US) | 1999-03-09 | — | — | US | disclosed |
| US-5804602-A | N-ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-09-08 | — | — | US | disclosed |
| US-5672592-A | HYDROLASE INHIBITORS, ANTITUMOR AND ANTICARCINOGENIC AGENTS, FOR PROSTATE CANCER | GUILFORD PHARMACEUTICALS INC. (US) | 1997-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207299-A1 | ORGAN PROTECTION IN PSMA-TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER | FOLH1, SHBG, KLK3 | FOLH1 1/4885GRM3 3265/4885GCLC 2055/4885 |
| US-12496292-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | FOLH1 1/4885GRM3 772/4885GCLC 1429/4885 |
| US-20250127939-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | VHL, PC, NPC1 | FOLH1 157/4885GRM3 1215/4885GCLC 1586/4885 |
| US-10668174-B2 | Organ protection in PSMA-targeted radionuclide therapy of prostate cancer | FOLH1, SHBG, KLK3 | FOLH1 1/4885GRM3 3265/4885GCLC 2055/4885 |
| US-20260007756-A1 | COMPOUND AND USE THEREOF | FOLH1, TRPV6, FOLR1 | FOLH1 1/4885GRM3 386/4885GCLC 3341/4885 |
| US-20250064948-A1 | GCPII INHIBITION FOR THE TREATMENT OF SARCOPENIA AND AGING | DGKI, PGC, MPC2 | FOLH1 149/4885GRM3 384/4885GCLC 300/4885 |
| US-20160067361-A1 | ORGAN PROTECTION IN PSMA-TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER | FOLH1, SHBG, KLK3 | FOLH1 1/4885GRM3 3265/4885GCLC 2055/4885 |
| US-11167049-B2 | Organ protection in PSMA-targeted radionuclide therapy of prostate cancer | FOLH1, SHBG, KLK3 | FOLH1 1/4885GRM3 3265/4885GCLC 2055/4885 |
| US-20200254120-A1 | ORGAN PROTECTION IN PSMA-TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER | FOLH1, SHBG, KLK3 | FOLH1 1/4885GRM3 3265/4885GCLC 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.